Duality Advisers LP Acquires New Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Share on StockTwits

Duality Advisers LP bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 18,718 shares of the biopharmaceutical company’s stock, valued at approximately $1,440,000.

Other hedge funds have also added to or reduced their stakes in the company. Baldwin Brothers Inc. MA boosted its stake in shares of Gilead Sciences by 63.3% during the first quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 136 shares during the period. Bainco International Investors bought a new stake in Gilead Sciences during the 1st quarter valued at about $29,000. EPG Wealth Management LLC boosted its position in Gilead Sciences by 186.7% in the 1st quarter. EPG Wealth Management LLC now owns 410 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 267 shares during the period. Harwood Advisory Group LLC bought a new position in Gilead Sciences in the 1st quarter worth about $38,000. Finally, Modus Advisors LLC purchased a new position in shares of Gilead Sciences during the second quarter worth approximately $38,000. Institutional investors and hedge funds own 78.74% of the company’s stock.

In other news, CAO Diane E. Wilfong sold 12,264 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $80.09, for a total value of $982,223.76. Following the sale, the chief accounting officer now directly owns 23,685 shares of the company’s stock, valued at approximately $1,896,931.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Brett A. Pletcher sold 13,210 shares of the company’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total transaction of $1,046,628.30. Following the completion of the sale, the executive vice president now directly owns 27,204 shares in the company, valued at $2,155,372.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,079 shares of company stock valued at $2,240,630. Company insiders own 0.13% of the company’s stock.

Several research analysts recently issued reports on the company. Royal Bank of Canada dropped their price objective on Gilead Sciences from $89.00 to $87.00 and set an “outperform” rating on the stock in a research note on Friday. Raymond James downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating in a research report on Friday, May 1st. Wells Fargo & Co decreased their price objective on Gilead Sciences from $87.00 to $76.00 and set an “equal weight” rating for the company in a report on Friday. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Tuesday, June 30th. Finally, Oppenheimer reissued a “buy” rating on shares of Gilead Sciences in a research report on Monday, May 18th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and nine have assigned a buy rating to the company. Gilead Sciences presently has an average rating of “Hold” and an average price target of $79.63.

Shares of Gilead Sciences stock opened at $69.53 on Friday. The firm’s 50 day simple moving average is $75.47 and its two-hundred day simple moving average is $73.57. The firm has a market capitalization of $87.22 billion, a price-to-earnings ratio of -289.70, a PEG ratio of 2.34 and a beta of 0.70. Gilead Sciences, Inc. has a 12-month low of $60.89 and a 12-month high of $85.97. The company has a current ratio of 3.04, a quick ratio of 2.92 and a debt-to-equity ratio of 1.00.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.46). The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.24 billion. Gilead Sciences had a negative net margin of 1.16% and a positive return on equity of 32.17%. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 6.79 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 3.91%. Gilead Sciences’s dividend payout ratio is presently 44.30%.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: What are trading strategies for the 52-week high/low?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 

Latest News

Different Types of Research Papers
Different Types of Research Papers
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing


 
© 2006-2020 BBNS.